Christine M Swanson1, Carrie M Nielson, Smriti Shrestha, Christine G Lee, Elizabeth Barrett-Connor, Ivo Jans, Jane A Cauley, Steven Boonen, Roger Bouillon, Dirk Vanderschueren, Eric S Orwoll. 1. Division of Endocrinology (C.M.S., C.G.L., E.S.O.), Bone and Mineral Unit (C.M.S., C.M.N., S.S., C.G.L., E.S.O.), and Department of Public Health and Preventive Medicine (C.M.N.), Oregon Health & Science University, Portland, Oregon 97239; Research Service (C.G.L.), Portland Veterans Affairs Medical Center, Portland, Oregon 97239; Division of Epidemiology (E.B.-C.), Department of Family & Preventive Medicine, University California San Diego, La Jolla, California 92093-0607; Laboratory of Diagnostic Medicine (I.J., D.V.), KU Leuven, University of Leuven, 3000 Leuven, Belgium; Department of Epidemiology (J.A.C.), Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania 15261; and Division of Geriatric Medicine and Centre for Metabolic Bone Diseases (S.B.), and Laboratory of Clinical and Experimental Endocrinology (R.B., D.V.), KU Leuven, University of Leuven, 3000 Leuven, Belgium.
Abstract
CONTEXT: Despite common use of supplemental vitamin D2 in clinical practice, the associations of serum vitamin D2 concentrations with other vitamin D metabolites and total vitamin D are unclear. OBJECTIVE: The aim of the study was to measure vitamin D2 and D3 levels and examine their associations with each other and with total vitamin D. DESIGN: We performed a cross-sectional analysis of 679 randomly selected participants from the Osteoporotic Fractures in Men Study. 25-Hydroxyvitamin D2 [25(OH)D2], 25(OH)D3, 1,25-dihydroxyvitamin D2 [1,25(OH)2D2], and 1,25(OH)2D3 were measured using liquid chromatography-tandem mass spectrometry and were summed to obtain total 25(OH)D and 1,25(OH)2D. Associations between all metabolites (D2, D3, and total levels) were examined using Wilcoxon rank-sum tests and Spearman correlations. RESULTS: 25(OH)D2 and 1,25(OH)2D2 were detectable in 189 (27.8%) and 178 (26.2%) of the men, respectively. Higher 25(OH)D2 levels did not correlate with higher total 25(OH)D (r = 0.10; P = .17), although median total 25(OH)D was slightly higher in those with detectable vs undetectable 25(OH)D2 (25.8 vs 24.3 ng/mL; P < .001). 25(OH)D2 was not positively associated with total 1,25(OH)2D levels (r = -0.11; P = .13), and median 1,25(OH)2D level was not higher in those with detectable vs undetectable 25(OH)D2. Higher 25(OH)D2 was associated with lower 25(OH)D3 (r = -0.35; P < .001) and 1,25(OH)2D3 (r = -0.32; P < .001), with median levels of both D3 metabolites 18-35% higher when D2 metabolites were undetectable. CONCLUSIONS: In a cohort of older men, 25(OH)D2 is associated with lower levels of 25(OH)D3 and 1,25(OH)2D3, suggesting that vitamin D2 may decrease the availability of D3 and may not increase calcitriol levels.
CONTEXT: Despite common use of supplemental vitamin D2 in clinical practice, the associations of serum vitamin D2 concentrations with other vitamin D metabolites and total vitamin D are unclear. OBJECTIVE: The aim of the study was to measure vitamin D2 and D3 levels and examine their associations with each other and with total vitamin D. DESIGN: We performed a cross-sectional analysis of 679 randomly selected participants from the Osteoporotic Fractures in Men Study. 25-Hydroxyvitamin D2 [25(OH)D2], 25(OH)D3, 1,25-dihydroxyvitamin D2 [1,25(OH)2D2], and 1,25(OH)2D3 were measured using liquid chromatography-tandem mass spectrometry and were summed to obtain total 25(OH)D and 1,25(OH)2D. Associations between all metabolites (D2, D3, and total levels) were examined using Wilcoxon rank-sum tests and Spearman correlations. RESULTS:25(OH)D2 and 1,25(OH)2D2 were detectable in 189 (27.8%) and 178 (26.2%) of the men, respectively. Higher 25(OH)D2 levels did not correlate with higher total 25(OH)D (r = 0.10; P = .17), although median total 25(OH)D was slightly higher in those with detectable vs undetectable 25(OH)D2 (25.8 vs 24.3 ng/mL; P < .001). 25(OH)D2 was not positively associated with total 1,25(OH)2D levels (r = -0.11; P = .13), and median 1,25(OH)2D level was not higher in those with detectable vs undetectable 25(OH)D2. Higher 25(OH)D2 was associated with lower 25(OH)D3 (r = -0.35; P < .001) and 1,25(OH)2D3 (r = -0.32; P < .001), with median levels of both D3 metabolites 18-35% higher when D2 metabolites were undetectable. CONCLUSIONS: In a cohort of older men, 25(OH)D2 is associated with lower levels of 25(OH)D3 and 1,25(OH)2D3, suggesting that vitamin D2 may decrease the availability of D3 and may not increase calcitriol levels.
Authors: Michael F Holick; Neil C Binkley; Heike A Bischoff-Ferrari; Catherine M Gordon; David A Hanley; Robert P Heaney; M Hassan Murad; Connie M Weaver Journal: J Clin Endocrinol Metab Date: 2011-06-06 Impact factor: 5.958
Authors: Kristine E Ensrud; Brent C Taylor; Misti L Paudel; Jane A Cauley; Peggy M Cawthon; Steven R Cummings; Howard A Fink; Elizabeth Barrett-Connor; Joseph M Zmuda; James M Shikany; Eric S Orwoll Journal: J Clin Endocrinol Metab Date: 2009-05-19 Impact factor: 5.958
Authors: A Catharine Ross; JoAnn E Manson; Steven A Abrams; John F Aloia; Patsy M Brannon; Steven K Clinton; Ramon A Durazo-Arvizu; J Christopher Gallagher; Richard L Gallo; Glenville Jones; Christopher S Kovacs; Susan T Mayne; Clifford J Rosen; Sue A Shapses Journal: J Clin Endocrinol Metab Date: 2010-11-29 Impact factor: 5.958
Authors: H A Bischoff-Ferrari; B Dawson-Hughes; H B Staehelin; J E Orav; A E Stuck; R Theiler; J B Wong; A Egli; D P Kiel; J Henschkowski Journal: BMJ Date: 2009-10-01
Authors: Dirk Vanderschueren; Stephen R Pye; Terence W O'Neill; David M Lee; Ivo Jans; Jaak Billen; Evelien Gielen; Michaël Laurent; Frank Claessens; Judith E Adams; Kate A Ward; Gyorgy Bartfai; Felipe F Casanueva; Joseph D Finn; Gianni Forti; Aleksander Giwercman; Thang S Han; Ilpo T Huhtaniemi; Krzysztof Kula; Michael E J Lean; Neil Pendleton; Margus Punab; Frederick C W Wu; Steven Boonen Journal: J Clin Endocrinol Metab Date: 2013-02-05 Impact factor: 5.958
Authors: Jane A Cauley; Neeta Parimi; Kristine E Ensrud; Douglas C Bauer; Peggy M Cawthon; Steven R Cummings; Andrew R Hoffman; James M Shikany; Elizabeth Barrett-Connor; Eric Orwoll Journal: J Bone Miner Res Date: 2010-03 Impact factor: 6.741
Authors: Christine M Swanson; Priya Srikanth; Christine G Lee; Steven R Cummings; Ivo Jans; Jane A Cauley; Roger Bouillon; Dirk Vanderschueren; Eric S Orwoll; Carrie M Nielson Journal: J Bone Miner Res Date: 2015-05-22 Impact factor: 6.741
Authors: Albert Shieh; Rene F Chun; Christina Ma; Sten Witzel; Briana Meyer; Brandon Rafison; Leon Swinkels; Tonnie Huijs; Sam Pepkowitz; Brett Holmquist; Martin Hewison; John S Adams Journal: J Clin Endocrinol Metab Date: 2016-05-18 Impact factor: 5.958
Authors: Zona Batacchi; Cassianne Robinson-Cohen; Andrew N Hoofnagle; Tamara Isakova; Bryan Kestenbaum; Kevin J Martin; Myles S Wolf; Ian H de Boer Journal: Clin J Am Soc Nephrol Date: 2017-08-02 Impact factor: 8.237
Authors: Ewelina A Dziedzic; Jakub S Gąsior; Mariusz Pawłowski; Beata Wodejko-Kucharska; Tomasz Saniewski; Anna Marcisz; Marek J Dąbrowski Journal: Arch Med Sci Date: 2019-03-04 Impact factor: 3.318
Authors: Lourdes Herrera-Quintana; Yenifer Gamarra-Morales; Héctor Vázquez-Lorente; Jorge Molina-López; José Castaño-Pérez; Juan Francisco Machado-Casas; Ramón Coca-Zúñiga; José Miguel Pérez-Villares; Elena Planells Journal: Nutrients Date: 2021-06-09 Impact factor: 5.717
Authors: N G Forouhi; R K Menon; S J Sharp; N Mannan; P M Timms; A R Martineau; A P Rickard; B J Boucher; T A Chowdhury; C J Griffiths; S E Greenwald; S J Griffin; G A Hitman Journal: Diabetes Obes Metab Date: 2016-02-04 Impact factor: 6.577